Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ian F Pollack

Showing results (241-250 of 308) with videos related to

Pageof 31
Sort By:
Annals of Neurology|June 3, 2021
Longitudinal CSF Iron Pathway Proteins in Posthemorrhagic Hydrocephalus: Associations with Ventricle Size and Neurodevelopmental OutcomesJennifer M Strahle, Kelly B Mahaney, Diego M Morales, et al.
Frontiers in Immunology|May 24, 2021
TIGIT and PD-1 Immune Checkpoint Pathways Are Associated With Patient Outcome and Anti-Tumor Immunity in GlioblastomaItay Raphael, Rajeev Kumar, Lauren H McCarl, et al.
Plos One|March 10, 2021
Cerebrospinal fluid NCAM-1 concentration is associated with neurodevelopmental outcome in post-hemorrhagic hydrocephalus of prematurityDavid D Limbrick, Diego M Morales, Chevis N Shannon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 15, 2010
Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant gliomaHideho Okada, Pawel Kalinski, Ryo Ueda, et al.
Journal of Neurosurgery. Pediatrics|January 23, 2026
Clinical presentation of hydrocephalus following pre- and postnatal myelomeningocele repair: a Hydrocephalus Clinical Research Network studySasidhar Karuparti, Hailey Jensen, Ron W Reeder, et al.
Journal of Neurosurgery. Pediatrics|July 28, 2022
Hydrocephalus surveillance following CSF diversion: a modified Delphi studyDavid S Hersh, Jonathan E Martin, Ruth E Bristol, et al.
The Journal of Experimental Medicine|December 6, 2017
Novel and shared neoantigen derived from histone 3 variant H3.3K27M mutation for glioma T cell therapyZinal S Chheda, Gary Kohanbash, Kaori Okada, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 18, 2018
Extensive Molecular and Clinical Heterogeneity in Patients With Histologically Diagnosed CNS-PNET Treated as a Single Entity: A Report From the Children's Oncology Group Randomized ACNS0332 TrialEugene I Hwang, Marcel Kool, Peter C Burger, et al.
Brain Pathology (Zurich, Switzerland)|March 5, 2013
Histological predictors of outcome in ependymoma are dependent on anatomic site within the central nervous systemAditya Raghunathan, Khalida Wani, Terri S Armstrong, et al.
Neuro-Oncology Advances|April 10, 2024
Vorinostat, temozolomide or bevacizumab with irradiation and maintenance BEV/TMZ in pediatric high-grade glioma: A Children's Oncology Group StudyRishi R Lulla, Allen Buxton, Mark D Krailo, et al.
Pageof 31

Showing results (241-250 of 308) with videos related to

Sort By:
Pageof 31
Annals of Neurology|June 3, 2021
Longitudinal CSF Iron Pathway Proteins in Posthemorrhagic Hydrocephalus: Associations with Ventricle Size and Neurodevelopmental OutcomesJennifer M Strahle, Kelly B Mahaney, Diego M Morales, et al.
Frontiers in Immunology|May 24, 2021
TIGIT and PD-1 Immune Checkpoint Pathways Are Associated With Patient Outcome and Anti-Tumor Immunity in GlioblastomaItay Raphael, Rajeev Kumar, Lauren H McCarl, et al.
Plos One|March 10, 2021
Cerebrospinal fluid NCAM-1 concentration is associated with neurodevelopmental outcome in post-hemorrhagic hydrocephalus of prematurityDavid D Limbrick, Diego M Morales, Chevis N Shannon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 15, 2010
Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant gliomaHideho Okada, Pawel Kalinski, Ryo Ueda, et al.
Journal of Neurosurgery. Pediatrics|January 23, 2026
Clinical presentation of hydrocephalus following pre- and postnatal myelomeningocele repair: a Hydrocephalus Clinical Research Network studySasidhar Karuparti, Hailey Jensen, Ron W Reeder, et al.
Journal of Neurosurgery. Pediatrics|July 28, 2022
Hydrocephalus surveillance following CSF diversion: a modified Delphi studyDavid S Hersh, Jonathan E Martin, Ruth E Bristol, et al.
The Journal of Experimental Medicine|December 6, 2017
Novel and shared neoantigen derived from histone 3 variant H3.3K27M mutation for glioma T cell therapyZinal S Chheda, Gary Kohanbash, Kaori Okada, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 18, 2018
Extensive Molecular and Clinical Heterogeneity in Patients With Histologically Diagnosed CNS-PNET Treated as a Single Entity: A Report From the Children's Oncology Group Randomized ACNS0332 TrialEugene I Hwang, Marcel Kool, Peter C Burger, et al.
Brain Pathology (Zurich, Switzerland)|March 5, 2013
Histological predictors of outcome in ependymoma are dependent on anatomic site within the central nervous systemAditya Raghunathan, Khalida Wani, Terri S Armstrong, et al.
Neuro-Oncology Advances|April 10, 2024
Vorinostat, temozolomide or bevacizumab with irradiation and maintenance BEV/TMZ in pediatric high-grade glioma: A Children's Oncology Group StudyRishi R Lulla, Allen Buxton, Mark D Krailo, et al.
Pageof 31